Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational In Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors

Assay and Drug Development Technologies
Sajad ShahbaziRanbir Chander Sobti

Abstract

Alzheimer's disease (AD), a worldwide renowned progressive neurodegenerative disorder, is the most common cause of dementia. There are several studies on the important role of cholesterol metabolism in AD pathogenesis, which indicated that the high concentrations of serum cholesterol increase the risk of AD. Biosynthesis of the plasma cholesterol and other isoprenoids is catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) through the conversion of HMG-CoA to mevalonic acid in mevalonate pathway. Normally, the high level of plasma cholesterol is downregulated by HGMCR inhibition as the result of degradation of LDL, but in abnormal conditions, for example, high blood glucose, the HMGCR over activated resulting in uncontrolled blood cholesterol. Selective HMGCR inhibitor drugs such as statins, which increase the catabolism of plasma LDL and reduce the plasma concentration of cholesterol, have been investigated as a possible treatment for AD. In the present study, we have identified the binding modes of 22 various derivatives of 3-sulfamoylpyrroles 16, prepared via a [3 + 2] cycloaddition of a münchnone with a sulfonamide-substituted alkyne, by using efficient biocomputational tools. Out of 22, 5 ligands, with code number...Continue Reading

References

Jan 1, 1976·Advances in Lipid Research·V W RodwellJ J Mitschelen
Jan 1, 1986·Journal of Neuropathology and Experimental Neurology·T I Mandybur
Jun 1, 1997·The Journal of Physiology·N ChiesaE Wanke
Dec 10, 1999·Journal of Medicinal Chemistry· AjayM A Murcko
May 8, 2001·Trends in Pharmacological Sciences·J I VandenbergT J Campbell
Mar 30, 2002·Advanced Drug Delivery Reviews·William J Egan, Georgio Lauri
Jul 20, 2002·Journal of Cardiovascular Pharmacology·Helmut SinzingerBernhard A Peskar
May 19, 2004·Archives of Neurology·Christiane ReitzRichard Mayeux
Feb 19, 2005·Drug Discovery Today·Alex M Aronov
Dec 25, 2007·Bioorganic & Medicinal Chemistry Letters·William K C ParkCatherine Sekerke
Sep 9, 2008·Biochemical Pharmacology·Preetha AnandBharat B Aggarwal
Oct 29, 2009·Human Mutation·Paula L HedleyMichael Christiansen
Jan 6, 2010·Journal of Neurochemistry·Ian J MartinsRalph N Martins
Oct 20, 2010·Neuron·Lars BertramRudolph E Tanzi
Mar 31, 2011·Nature Reviews. Neuroscience·Gilbert Di Paolo, Tae-Wan Kim
Apr 8, 2011·Expert Review of Neurotherapeutics·Angel Cedazo-MínguezLaura Mateos
Apr 17, 2013·Clinical Pharmacology and Therapeutics·K L R BrouwerUNKNOWN International Transporter Consortium
May 23, 2013·The Journal of Biological Chemistry·Laura J Sharpe, Andrew J Brown

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
PISA

Software Mentioned

Glide
LigPrep
Schrödinger Suite
QPlogHERG
OPLS
Protein Preparation Wizard of Schrodinger Suite
XP
Schrödinger
ProPrep
Prime

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.